Ugo De Giorgi
About
Ugo De Giorgi is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research.
According to data from OpenAlex, Ugo De Giorgi has authored 489 papers receiving a total of 9.0k indexed citations (citations by other indexed papers that have themselves been cited), including 317 papers in Pulmonary and Respiratory Medicine, 234 papers in Oncology and 132 papers in Cancer Research. Recurrent topics in Ugo De Giorgi's work include Prostate Cancer Treatment and Research (162 papers), Renal cell carcinoma treatment (84 papers) and Cancer Immunotherapy and Biomarkers (72 papers). Ugo De Giorgi is often cited by papers focused on Prostate Cancer Treatment and Research (162 papers), Renal cell carcinoma treatment (84 papers) and Cancer Immunotherapy and Biomarkers (72 papers). Ugo De Giorgi collaborates with scholars based in Italy, United States and United Kingdom. Ugo De Giorgi's co-authors include Vincenza Conteduca, Emanuela Scarpi, Michal Mego, Giuseppe Schepisi, Cristian Lolli, Massimo Cristofanilli, Dino Amadori, Giorgia Gurioli, Salvatore Luca Burgio and James M. Reuben and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Investigation.
In The Last Decade
Ugo De Giorgi
465 papers receiving 8.9k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Ugo De Giorgi Italy | 51 | 4.7k | 3.8k | 2.4k | 2.3k | 2.1k | 489 | 9.0k | ||
| Aude Fléchon France | 33 | 4.9k 1.1× | 2.6k 0.7× | 1.5k 0.6× | 1.8k 0.8× | 2.0k 0.9× | 273 | 7.7k | ||
| Christine Théodore France | 39 | 6.0k 1.3× | 3.5k 0.9× | 1.7k 0.7× | 2.1k 0.9× | 3.9k 1.8× | 164 | 10.5k | ||
| George Fountzilas Greece | 54 | 3.7k 0.8× | 7.7k 2.0× | 2.1k 0.9× | 3.1k 1.4× | 2.3k 1.1× | 576 | 12.8k | ||
| Robert W. Ross United States | 27 | 3.5k 0.8× | 6.1k 1.6× | 1.9k 0.8× | 3.9k 1.7× | 1.6k 0.7× | 61 | 11.1k | ||
| Paul Elson United States | 60 | 5.6k 1.2× | 4.7k 1.2× | 2.6k 1.1× | 4.5k 2.0× | 3.2k 1.5× | 334 | 13.4k | ||
| Christian Kollmannsberger Canada | 63 | 8.7k 1.9× | 4.8k 1.3× | 3.4k 1.4× | 5.5k 2.4× | 4.2k 2.0× | 387 | 14.0k | ||
| Hedy L. Kindler United States | 61 | 7.3k 1.6× | 8.4k 2.2× | 3.1k 1.3× | 3.6k 1.6× | 1.8k 0.9× | 400 | 16.1k | ||
| I. Bodrogi Hungary | 20 | 6.4k 1.4× | 3.6k 0.9× | 2.9k 1.2× | 4.3k 1.9× | 2.4k 1.1× | 78 | 10.3k | ||
| David Olmos United Kingdom | 48 | 6.3k 1.3× | 4.1k 1.1× | 3.2k 1.3× | 3.2k 1.4× | 684 0.3× | 233 | 10.4k | ||
| Alan Horwich United Kingdom | 45 | 5.6k 1.2× | 2.6k 0.7× | 1.5k 0.6× | 2.0k 0.9× | 2.4k 1.1× | 140 | 10.4k |
Countries citing papers authored by Ugo De Giorgi
Since
Specialization
Citations
This map shows the geographic impact of Ugo De Giorgi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ugo De Giorgi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ugo De Giorgi more than expected).
Fields of papers citing papers by Ugo De Giorgi
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Ugo De Giorgi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ugo De Giorgi. The network helps show where Ugo De Giorgi may publish in the future.
Co-authorship network of co-authors of Ugo De Giorgi
This figure shows the co-authorship network connecting the top 25 collaborators of Ugo De Giorgi. A scholar is included among the top collaborators of Ugo De Giorgi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ugo De Giorgi. Ugo De Giorgi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Giorgi, Ugo De, Stephen J. Freedland, Antti Rannikko, et al.. (2025). Enzalutamide in patients with high-risk biochemically recurrent prostate cancer according to the European Association of Urology definition: a post hoc analysis of EMBARK. Prostate Cancer and Prostatic Diseases. 29(1). 198–201.
2.
Freedland, Stephen J., John P. Mulhall, Martin Gleave, et al.. (2025). Effects of Enzalutamide on the Sexual Activity of Patients with Biochemically Recurrent Prostate Cancer: A Post Hoc Analysis of Patient-reported Outcomes in the EMBARK Study. European Urology. 87(5). 507–511.
3.
Fizazi, Karim, Arun Azad, Nobuaki Matsubara, et al.. (2025). Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial. The Lancet. 406(10502). 461–474.
4.
Campione, Marina, Sara Elena Rebuzzi, Lucia Fratino, et al.. (2025). Prognostic Value of G8 Geriatric Screening and Meet-URO Scores in Metastatic Renal Cell Carcinoma Patients Receiving First-Line Ipilimumab-Nivolumab Combination Immunotherapy. Technology in Cancer Research & Treatment. 24. 2244058514–2244058514.
5.
Nehme, Jamil, Sara Bravaccini, Michele Zanoni, et al.. (2025). Pharmacological CDK4/6 inhibition promotes vulnerability to lysosomotropic agents in breast cancer. The EMBO Journal. 44(7). 1921–1942.
6.
Giunta, Emilio Francesco, Nicole Brighi, Giorgia Gurioli, et al.. (2024). 177Lu-PSMA therapy in metastatic prostate cancer: An updated review of prognostic and predictive biomarkers. Cancer Treatment Reviews. 125. 102699–102699.
7.
Azad, Arun, Karim Fizazi, Douglas Laird, et al.. (2024). Utility of ctDNA burden as a prognostic biomarker for efficacy in TALAPRO-2: A phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 42(16_suppl). 5020–5020.
8.
Giunta, Emilio Francesco, Umberto Malapelle, Antonio Russo, & Ugo De Giorgi. (2023). Blood-based liquid biopsy in advanced prostate cancer. Critical Reviews in Oncology/Hematology. 194. 104241–104241.
9.
Campone, Mario, François‐Clément Bidard, Patrick Neven, et al.. (2023). AMEERA-4: a randomized, preoperative window-of-opportunity study of amcenestrant versus letrozole in early breast cancer. Breast Cancer Research. 25(1). 141–141.
10.
Sternberg, Cora N., Yohann Loriot, Ernest Choy, et al.. (2023). Final results from SAUL, a single-arm international real-world study of atezolizumab (atezo) in 1004 patients (pts) with pretreated locally advanced/metastatic urinary tract carcinoma (UTC).. Journal of Clinical Oncology. 41(16_suppl). 4569–4569.
11.
Cursano, Maria Concetta, Emilio Francesco Giunta, Emanuela Scarpi, et al.. (2023). Impact of Somatic DNA Repair Mutations on the Clinical Outcomes of Bone Metastases from Castration-Resistant Prostate Cancer. International Journal of Molecular Sciences. 24(15). 12436–12436.
12.
Palleschi, Michela, Andrea Prochowski Iamurri, Emanuela Scarpi, et al.. (2022). Computed tomography based analyses of body mass composition in HER2 positive metastatic breast cancer patients undergoing first line treatment with pertuzumab and trastuzumab. Scientific Reports. 12(1). 3385–3385.
13.
Bartoletti, Michele, Alice Bergamini, Gaia Giannone, et al.. (2022). A fully virtual and nationwide molecular tumor board for gynecologic cancer patients: the virtual experience of the MITO cooperative group. International Journal of Gynecological Cancer. 32(9). 1205–1207.
14.
Catalano, Martina, Ugo De Giorgi, Marco Maruzzo, et al.. (2022). Long-Term Response to Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma. Biomedicines. 10(10). 2444–2444.
15.
Bersanelli, Melissa, Giulia Mazzaschi, Patrizia Giannatempo, et al.. (2021). Immunotherapy and Sonpavde score validation in advanced upper tract urothelial carcinoma: a retrospective study by the Italian Network for Research in Urologic-Oncology (Meet-URO group). Immunotherapy. 14(2). 107–114.
16.
Cerchione, Claudio, Giovanni Martinelli, Marco Picardi, et al.. (2020). Combined Oral Fentanyl Citrate and Midazolam as Premedication for Bone Marrow Aspiration and Biopsy in Patients with Hematological Malignancies: A Randomized, Controlled and Patient-Blinded Clinical Trial. Journal of Clinical Medicine. 9(2). 395–395.
17.
Banna, Giuseppe Luigi, Rosario Di Quattro, Lorenzo Malatino, et al.. (2020). Neutrophil-to-lymphocyte ratio and lactate dehydrogenase as biomarkers for urothelial cancer treated with immunotherapy. Clinical & Translational Oncology. 22(11). 2130–2135.
18.
Bono, Johann S. de, Ugo De Giorgi, Daniel Nava Rodrigues, et al.. (2018). Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss. Clinical Cancer Research. 25(3). 928–936.
19.
Pedrazzoli, Paolo, Giovanni Martinelli, Alessandro M. Gianni, et al.. (2014). Adjuvant High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Support for High-Risk Primary Breast Cancer: Results from the Italian National Registry. Biology of Blood and Marrow Transplantation. 20(4). 501–506.
20.
Eechoute, Karel, Martin N. Fransson, Floris A. de Jong, et al.. (2012). A Long-term Prospective Population Pharmacokinetic Study on Imatinib Plasma Concentrations in GIST Patients. Clinical Cancer Research. 18(20). 5780–5787.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Aude Fléchon Breakdown of academic impact, for papers by Christine Théodore Breakdown of academic impact, for papers by George Fountzilas Breakdown of academic impact, for papers by Robert W. Ross Breakdown of academic impact, for papers by Paul Elson Breakdown of academic impact, for papers by Christian Kollmannsberger Breakdown of academic impact, for papers by Hedy L. Kindler Breakdown of academic impact, for papers by I. Bodrogi Breakdown of academic impact, for papers by David Olmos Breakdown of academic impact, for papers by Alan Horwich